Angiotensin II type 1 receptor expression in polymorphonuclear leukocytes from high-risk subjects: Changes after treatment with simvastatin

Journal of Cardiovascular Pharmacology

Volumn 49, Issue 5, 2007, Pages 299-305

  Marino, Franca ^a   Guasti, Luigina ^a   Cosentino, Marco ^a   Ferrari, Marco ^a   Rasini, Emanuela ^a   Maio, Ramona Consuelo ^a   Cimpanelli, Maria Grazia ^a   Cereda, Elena ^a   Crespi, Chiara ^a   Simoni, Cinzia ^a   Restelli, Daniela ^a   Venco, Achille ^a   Lecchini, Sergio ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Angiotensin II; Angiotensin II type 1 receptor; Flow cytometry; Polymorphonuclear leukocytes; Real time PCR; Simvastatin

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; GUANOSINE TRIPHOSPHATE; MESSENGER RNA; RAC1 PROTEIN; SIMVASTATIN;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CELL MEMBRANE; CLINICAL ARTICLE; DOWN REGULATION; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADULT; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL MEMBRANE; CORONARY DISEASE; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITALY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUTROPHILS; RAC1 GTP-BINDING PROTEIN; RECEPTOR, ANGIOTENSIN, TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIMVASTATIN; TREATMENT OUTCOME;

EID: 34249807007     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31803d35ce     Document Type: Article

References (32)

1. Brasier AR, Recinos A, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002;22:1257-1266.
2. 1-type angiotensin receptor in oxidative stress and atherogenesis. Part I: oxidative stress and atherogenesis. Circulation. 2002;105:393-396.
3. Phillips MI, Kagiyama S. Angiotensin II as a pro-inflammatory mediator. Curr Opin Invest Drugs. 2002;3:569-577.
4. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006;98:121-128.
5. Nickenig G, Jung O, Strehlow K, et al. Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am J Physiol. 1997;272:H2701-H2707.
6. Nickenig G, Baümer AT, Temur Y, et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 1999;100:2131-2134.
7. Li DY, Zhang YC, Philips MI, et al. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res. 1999;84:1113-1115.
8. 1-receptor and implications for vascular disease. J Hypertens. 2006;24(Suppl 1):S15-S21.
9. Wassmann S, Laufs U, Anselm T, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001;59:646-654.
10. Delbosc S, Cristol JP, Descomps B, et al. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension. 2002;40:142-147.
11. Kugi M, Matsunaga A, Ono J, et al. Antioxidative effects of fluvastatin on superoxide anion activated by angiotensin II in human aortic smooth muscle cells. Cardiovasc Drugs Ther. 2002;16:203-207.
12. Graeme JH, MBSS, FRCP Edin, FRACP. Angiotensin-converting enzyme inhibitors for stroke prevention. Stroke. 2003;34:354-356.
13. Arntz HR. The case of early statin therapy in acute coronary syndromes. Cardiol Rev. 2002;10:91-96.
14. Chen CN, Chang SF, Lee PL, et al. Neutrophils, lymphocytes, and monocytes exhibit diverse behaviors in transendothelial and subendothelial migrations under coculture with smooth muscle cells in disturbed flow. Blood. 2006;107:1933-1942.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
16. Guasti L, Marino F, Cosentino M, et al. Simvastatin treatment modifies polymorphonuclear leukocyte function in high-risk subjects: a longitudinal study. J Hypertens. 2006;24:2423-2430.
17. Nèegre-Aminou P, van Erck M, van Leeuwen REW, et al. Differential effect of simvastatin on various signal transduction intermediates in cultured human smooth muscle cells. Biochem Pharmacol. 2001;61:991-998.
18. Rasini E, Cosentino M, Marino F, et al. Angiotensin II type 1 receptor expression on human leukocyte subsets: a flow cytometric and RT-PCR study. Regulatory Peptides. 2006;134:69-74.
19. Shimada K, Yazaki Y. Binding sites for angiotensin II in human mononuclear leukocytes. J Biochem. 1978;84:1013-1015.
20. Okamura A, Rakugi H, Ohishi M, et al. Upregulation of rennin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens. 1999;17:537-545.
21. Yamani MH, Cook DJ, Tuzcu EM, et al. Systemic up-regulation of angiotensin II type 1 receptor in cardiac donors with spontaneous intracerebral hemorrhage. Am J Transplant. 2004;4:1097-1102.
22. Reguzzoni M, Cosentino M, Rasini E, et al. Ultrastructural localization of tyrosine hydroxylase in human peripheral blood mononuclear cells: effect of stimulation with phytohaemagglutinin. Cell Tissue Res. 2002;310:297-304.
23. Morris AJ, Malbon CC. Physiological regulation of G protein-linked signaling. Physiol Rev. 1999;79:1373-1430.
24. Hazan-Halevy I, Levy T, Wolak T, et al. Stimulation of NADPH oxidase by angiotensin II in human neutrophils is mediated by ERK, p38 MAP-kinase and cytosolic phospholipase A2. J Hypertens. 2005;23:1183-1190.
25. Brown KA, Pearson JD, Edgeworth JD, et al. Neutrophils in development of multiple organ failure in sepsis. Lancet. 2006;368:157-169.
26. Kowalski J, Barylski M, Banach M, et al. Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J Cardiovasc Pharmacol. 2006;48:143-147.
27. Kawaguchi H, Mori T, Kawano T, et al. Band neutrophil count and the presence and severity of coronary atherosclerosis. Am Heart J. 1996;132:9-12.
28. Brumeau TD, Goldstein R, Casares S. Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors. Clin Immunol. 2006;119:1-12.
29. Arnaud C, Veillard NR, Mach F. Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis. Curr Drug Targets Cardiovasc Haematol Dis. 2005;5:127-134.
30. Wassmann S, Faul A, Hennen B, et al. Rapid effect of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res. 2003;104:376-379.
31. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertens. 1999;34:1281-1286.
32. Ray KK, Cannon CP. Intensive therapy in acute coronary syndromes: clinical benefits and vascular biology. Curr Opin Lipidol. 2004;15:637-643.